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BACKGROUND፡ Mycobacterial infections are known to cause 
a public health problem globally. The burden of pulmonary 
disease from nontuberculous mycobacteria is reportedly on the 
rise in different parts of the world despite the fact that there is 
limited data about the disease in sub-Saharan Africa including 
Ethiopia. Hence, we aimed to assess the magnitude of M. 
tuberculosis and nontuberculous mycobacteria (NTM) among 
presumptive pulmonary tuberculosis patients attending St. Paul’s 
hospital Medical College, Addis Ababa, Ethiopia. 
METHODS: A cross-sectional study was conducted from June to 
September 20/2016. Morning sputum specimens were collected, 
processed and cultured in Lowenstein Jensen medium and 
BACTEC MGIT 960 media. The nontuberculous mycobacteria 
were further confirmed and characterized by Genotype CM/AS 
assays. The socio-demographic, clinical and chest x-ray data were 
collected using a structured questionnaire. The data was analyzed 
using SPSS version 20. 
RESULTS: Out of 275 presumptive tuberculosis patients enrolled 
in the study, 29(10.5%) were culture positive for Mycobacteria. Of 
these, 3(10.3%) were found to be NTM and 26(89.6%) were 
Mycobacterium tuberculosis complex. Of the NTM, two were 
unidentified and one typed as M.peregrinum. There was no co-
isolation of Mycobacterium tuberculosis complex and 
nontuberculous mycobacteria. Overall, 6(23.1%) Mycobacterium 
tuberculosis complex isolates were resistant to at least one anti-
tuberculosis drug. Of these, two were multidrug resistant 
tuberculosis cases (7.7%) detected from previously treated 
patients. 
CONCLUSION: Relatively low magnitude of Mycobacterium 
tuberculosis complex and nontuberculous mycobacteria isolates 
were seen in the study area. Therefore, further study using a large 
sample size is needed to be done to consider nontuberculous 
mycobacteria infection as a differential diagnosis in presumptive 
pulmonary tuberculosis patients. 
KEYWORDS: Nontuberculous mycobacteria, Multi drug resistant 
tuberculosis, Mycobacterium tuberculosis complex 
 
                  








The genus Mycobacteria includes aerobic and 
non-motile organisms. They have a lipid rich 
cell wall which is thicker than most other 
bacteria (1). Both Mycobacterium tuberculosis 
and nontuberculous mycobacteria (NTM) 
classified in this genus are acid fast bacilli 
indistinguishably and cause chronic lung 
infections (2,3). They also share clinical 
manifestation, features of hardiness, 
hydrophobicity, aerosolization and intracellular 
pathogenicity (4,5). However, person-to-person 
transmission has not been convincingly reported 
in NTM pulmonary disease (6). 
Non-tuberculous mycobacteria encompass 
all Mycobacterium species that are not members 
of the Mycobacterium tuberculosis complex and 
Mycobacterium leprae. They are free-living 
organisms found ubiquitously in the 
environment mainly in soil and water. More than 
125 species of NTM are identified, 
approximately 60 of which are suspected or 
known to be pathogenic (7,8). NTM can cause 
chronic pulmonary disease, disseminated 
infection, lymphadenitis, and skin and soft tissue 
infection in both immunocompetent and 
immunocompromised individuals (7, 8, 9). 
Globally, over the past three decades 
prevalence of pulmonary NTM disease has 
increased dramatically (10). These could be 
partially due to factors like the development of 
microbiological isolation and identification 
techniques, pathogen, host and host parasite 
interaction factors (11). Increasing numbers of 
immune compromised patients, including those 
with Human Immune Deficiency Virus infection 
and hematological disorders are also implicated 
in increment of pulmonary disease due to NTM 
(8). Studies done in Canada and US indicate that 
pulmonary NTM (PNTM) disease is far more 
common than TB and causes higher morbidity 
than TB especially in elderly individuals 
(12,13).  
Ethiopia is one of the thirty high burden 
tuberculosis countries in the world (14). 
According to the 2019 World Health 
Organization’s global TB report, there were an 
estimated 165,000 incidence cases of 
tuberculosis (TB,) and the estimated TB cases 
with MDR/RR-TB in new and previously treated 
cases were 0.71% and 16% respectively (14).   
A lot of studies were conducted regarding 
the burden of Mycobacterium tuberculosis and 
their drug resistance profile in Ethiopia (15,16, 
17,18,19,20,21). However, in Ethiopia, very few 
studies report existence of nontuberculous 
mycobacteria without species identification 
(15,20). In addition, drug resistance profile and 
burden of the tuberculosis disease also need to 
be updated for effective management of 
tuberculosis patients. Accordingly, this study 
focused on assessing the magnitude of 
Mycobacterium tuberculosis and nontuberculous 
mycobacteria isolates and also determining the 
drug resistance profile of Mycobacterium 
tuberculosis isolates from presumptive 
pulmonary tuberculosis patients attending St. 
Paul's Hospital Millennium Medical College 
Addis Ababa, Ethiopia. 
 
MATERIALS AND METHODS 
 
Study design and Study population: A cross 
sectional study design was done from June to 
September 20/2016. Presumptive pulmonary 
tuberculosis patients who were attending St. 
Paul’s Hospital Millennium Medical College 
were enrolled to the study. It is the second 
largest public hospital in the nation which serves 
more than 110,000 people annually.  
 
Sample size determination and sampling 
technique: The minimum required sample size 
of the study was determined using the formula 
for a single population proportion. By 
considering prevalence of pulmonary 
tuberculosis as 21.3% from previous study done 
in Addis Ababa, Ethiopia (21), 95% confidence 
level and marginal error of 5%, the final sample 
size was 258. However, a total of 275 patients 
with presumptive pulmonary tuberculosis were 
consecutively included in this study.   
 
Data collection: After informed consent, socio-
demographic, health and behavioral factors, 
clinical history and chest x-ray data were 
collected from each participants using a 
structured questionnaire. In addition, about 3-5 
ml of morning sputum samples were collected 
using sterile, disposable, single-use, screw-
capped conical centrifuge tubes. It was 
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immediately transported to the national 
tuberculosis laboratory of Ethiopian public 
health institute for laboratory processing. 
 
Sample processing and smear microscopy: 
Sputum samples were mixed with an equal 
volume of N-acetyl-L-cysteine-sodium 
hydroxide (NALC-NAOH) solution and 
vortexed for less than 20 seconds and kept for 15 
minutes at 20-25 °C for the decontamination. 
Phosphate Buffered saline (PBS) was filled to a 
50 ml mark on the falcon tube and vortexed. It 
was centrifuged at 3000 g for 15 minutes and the 
supernatant was discarded. A portion of the 
sediments was used for culture and the other 
portion for Ziehl-Neelsen staining after 
resuspended in 1 ml PBS (22).  
Sputum smears of size 1 x 2 cm were made 
with new grease-free slides and allowed to air 
dry. The air dried smears were then fixed by 
gently passing over a flame 2-3 times. The 
smears including positive and negative controls 
were stained with Ziehl-Neelsen (ZN) technique. 
Examination and reporting of stained slides were 
performed by light microscopy (22).  
 
Culture and identification: Portion of each 
specimen sediment simultaneously inoculated 
into solid Lowenstein Jensen (2-3 drops) and 
BACTEC MGIT 960 media (Becton Dickinson, 
Franklin Lakes, NJ07417, USA) (0.5 ml). LJ 
medium cultures incubated in a 37°C for a 
maximum of eight weeks (monitored every 
week) whereas liquid culture was incubated in 
an automated BACTEC MGIT 960TM machine 
(Becton Dickinson Diagnostic Instrument 
Systems) for a maximum of 42 days to report 
negative. Cultures exhibiting growth were 
subjected to light microscopy for the presence of 
acid-fast bacteria and inoculated to blood agar 
(BAP) before being considered as positive for 
Mycobacteria (22). 
Isolates grown on blood agar after 
overnight incubation and no acid fast bacilli 
(AFB) seen on Ziehl-Neelson staining were 
considered as contaminants. However, isolates 
which showed no growth on BAP and positive 
for AFB were considered as Mycobacteria. In 
addition, isolates grown on BAP and AFB seen 
on Ziehl-Neelsen staining were considered as 
the presence of both contaminants and 
Mycobacteria (22). 
 
Capilia TB-Neo rapid test: Capilia TB-Neo 
rapid test was used to classify the mycobacteria 
into Mycobacterium tuberculosis complex 
(MTBC) and probable Nontuberculous 
mycobacteria. The Capilia TB-Neo Rapid test 
negative and positive growth were considered as 
probable NTM and MTBC respectively. 
Confirmation and characterization of the 
probable NTM was performed by Hain‟s 
GenoType® Mycobacterium CM and 
GenoType® Mycobacterium AS molecular 
genetic assays. 
 
DNA extraction and GenoType 
Mycobacterium CM/AS assay: 
Nontuberculous DNA was extracted from heat–
inactivated AFB isolates. Briefly, bacteria 
suspended in 500 µl sterile water or 1  ml 
directly from positive liquid media  were 
inactivated at 80 °C for 20 min, then ultra-
sonicated  at 35  kHz and heated at 100  °C for 
10  min each treatment and centrifuged at 16,100 
g two times for 5  minutes. The supernatant was 
taken as template DNA (23).  
GenoType® Mycobacterium CM/AS 
(HainLifescience GmbH, Nehren, Germany) 
assays were performed using the template DNA 
according to the manufacturer’s instructions. 
The GenoType CM assay was used to identify 
the common NTM species. GenoType AS assay 
was used to identify additional NTM species 
when the species are undetermined by the 
former assay. Those tests are based on the DNA 
strip technology. Three controls (conjugate, 
universal, and genus) are included in each strip 
(23).  
 
Drug susceptibility test: Phenotypic method 
using BACTEC-MGIT 960 SIRE Kits (Franklin 
Lakes, NJ, USA) was done on pure isolates of 
MTBC. It was performed for the first line anti-
tuberculosis drugs using BACTEC MGIT 960 
media. The critical concentration of each drug 
was 1µg/ml, 0.1µg/ml, 1µg/ml, 5µg/ml and 
100µg/ml for streptomycin, isoniazid, 
rifampicin, ethambutol and pyrazinamide 
respectively. The MGIT 960 system 
                  






automatically interpreted the results as 
susceptible or resistant (22). 
 
Statistical analysis: Data were collected, 
entered, and analyzed using SPSS version 20 
software. Categorical variables were described 
as proportion. Binary logistic regression was 
performed to check the presence of an 
association between MTBC and independent 
variables. A p-value less than 0.05 was 
considered as statistically significant. 
 
Ethics approval and consent to participate: 
Ethical clearance was obtained from the Ethical 
Review Committee of Medical Laboratory 
Sciences, College of Health Sciences, Addis 
Ababa University. Written informed consent 
was also obtained from all eligible study 
participants or assent from the guardians of 
participants younger than 18 years. Laboratory 




Characteristics of study participants: A total 
of 275 presumptive pulmonary tuberculosis 
patients with a predominance of males (150, 
54.5%) were enrolled. The mean age was 43 
years (± 6.6 SD) and the majority (33.1%) fell in 
the age range of 31-45 years (Table 1).  
Most (96.4%) of the participants were 
ambulatory patients. About 36(13.1%), 
75(27.3%) and 19(6.9%) of the study 
participants had HIV infection, history of 
previous tuberculosis treatment and diabetes 
mellitus respectively (Table 1). 
Clinical features and chest x-ray results of 
study participants: Persistent cough for more 
than two weeks and chest pain were observed in 
259(94.2%) and 228(82.9%) participants 
respectively. Of 224 participants with known 
chest x-ray results, 111(49.6%) showed different 







Table 1: Demographic, health and behavioral 
characteristics of 275 presumptive tuberculosis 
patients at St. Paul’s Hospital Millennium 
Medical College, 2016. 
 
Variable Frequency Percent 
Sex   
 Male 150 54.5 
        Female 125 45.5 
Residence   
Rural 95 34.5 
Urban 180 65.5 
Age   
16-30 78 28.4 
31-45 91 33.1 
46-60 62 22.5 
≥ 61 44                   16 
Educational level   
Illiterate 102 37.1 
< 6 42 15.3 
6-12 105 38.2 
Higher education  26  9.5 
Occupation   
Farming 84 30.5 
Office work/student 69 25.1 
House wife 75 27.3 
Others 47 17.1 
Previous TB  treatment       
Yes 75 27.3 
No 200 72.7 
HIV status              
Reactive 36 13.1 
Non-reactive 77 28 
Unknown 162 58.9 
Diabetes mellitus                 
Yes 19 6.9 
No 54 19.6 
Unknown 202 73.5 
Smoke cigarette   
Yes 16 5.8 
No 259 94.2 
Drink alcohol   
Yes 58 21.1 
No 217 78.9 
Chew Kchat                 
Yes 21 7.6 
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Table 2: Distribution of clinical and chest x-ray 
results of 275 presumptive tuberculosis patients at St. 
Paulo’s hospital millennium medical college, 2016. 
 
 
Magnitude of mycobacterium tuberculosis 
complex and nontuberculous mycobacteria: 
Twenty-nine (10.6%, 29/275) morning sputum 
samples were found to be culture positive for 
Mycobacteria. Of the 29 participants with 
confirmed mycobacteria, 26(89.7%) were 
MTBC and the remaining 3(10.3%) were NTM. 
Sputum smear microscopy identified TB in 12 
(45.2%) cases. These resulted in an overall 
magnitude of 9.5% (26/275) for MTBC and 
1.1% (3/275) for NTM. There was no co-
isolation of MTBC and NTM in the sputum 
samples examined. 
Of the three isolated nontuberculous 
mycobacteria, two were unidentified NTM and 
one was identified as Mycobacterium 
peregrinum. Two of the isolated NTM were 
rapid growers. All the NTM were negative for 
direct sputum smear microscopy.  
Mycobacterium tuberculosis magnitude and 
chest x-ray results: We assessed the chest x-ray 
profiles of 224 study subjects out of 275 
patients. The chest x-ray results of 51 patients 
(18.5 %, 51/275) were not available during data 
mining from the patient card. The radiologist 
reported normal chest x-ray results for 113 
subjects (113/ 224). However, 8 patients (7.1%, 
8/113) were positive for MTBC using culture 
(Table 3). 
Regarding nontuberculous mycobacteria, 
two were from patients who had normal chest x-
ray results and one from a patient who had 
abnormal chest x-ray result. 
 
Table 3: Frequency of Mycobacterium tuberculosis complex isolates along with chest x-ray results at St. 
Paul’s Hospital Millennium Medical College, 2016. 
 




Smear negative/ culture 
positive 
Normal 113 8(32%) 2 6 
Abnormal 111 17(68%) 10 7 
                        Total 224 25(100) 12 13 
MTBC- Mycobacterium tuberculosis complex
Table 4: Distribution of drug resistance pattern of 26 isolated Mycobacterium tuberculosis from patients 
at St. Paulo’s hospital millennium medical college, 2016. 
 
Sensitivity/Resistance Number (%) 
Sensitive to all drugs 20(76.9%) 
Single resistance  
Streptomycin 3(11.5%) 
Isoniazid 1(3.8%) 
Double resistance  
Rifampicin and Isoniazid 1(3.8 %) 
Triple resistance   
Rifampicin, Isoniazid, Streptomycin 1(3.8%) 
Variable Frequency Percent 
Cough ≥ 2 weeks       
Yes 259 94.2 
No 16 5.8 
Hemoptysis   
Yes 77 28 
No 198 72 
Night sweeting           
Yes 151 54.9 
No 124 45.1 
Fever   
Yes 182 66.2 
No 93 33.8 
Chest pain                  
Yes 228 82.9 
No 47 17.1 
Chest x-ray result       
Normal 113 41.1 
Abnormal 111 40.4 
Unknown 51 18.5 
                  






Drug resistant profile of Mycobacterium 
tuberculosis complex isolates: Of the twenty six 
isolated Mycobacterium tuberculosis complex, 
6(23.1%) isolates were resistant to at least one 
drug. The highest proportions of any drug 
resistance were observed in Streptomycin 4(15.4 
%) followed by Isoniazid 3(11.5 %). Two MDR 
cases (7.7%) were isolated from patients who 
had a previous tuberculosis treatment history 
(Table 4). 
Mycobacterium tuberculosis complex (MTBC) 
and associated factors: Larger proportion of 
females (9.6%, p=0.940), participants within the 
age range of 16-30 years (14.1%, p=0.119) and 
HIV infected patients (8.3%, p=0.723) were TB 
positive. The pulmonary TB positive and 
negative individuals had no significant 
differences concerning educational status, 
occupation, residence, marital status, HIV status, 
DM status, alcohol consumption, and smoking 
cigarette (Table 5).  
 
Table 5: Association between socio-demographic, behavioral, clinical characteristics and MTBC 
positivity of study participants at St. Paul’s Hospital Millennium Medical College, 2016. 
 
Variable Positive N (%)  COR (CI; 95%)  P-value   
Sex   
 
Male 14(53.8) 1.119(0.443-2.824) 0.940 
Female 12(46.2) I  
Residence    V0.393 
Rural 19(73.1) 1.484(0.6-3.666) 0.393 
Urban 7(26.9) I  
Age    
16-30 11(42.3) 0.290 (0.061-1.374) 0.119   
31-45 9(34.6) 0.434(0.090-2.099) 0.299 
46-60 4(15.4) 0.690(0.121-3.947) 0.677 
≥ 61 2(7.7) I  0.984 
Educational level    
Illiterate 5(19.2) 2.53(0.564-11.36) 0.226    
< 6 5(19.2) 0.965(0.210-4.427) 0.964 
6-12 13(50) 0.923(0.243-3.511) 0.907 0.9070.907 
Higher education 3(10.3) I  
Occupation    
Farming 8(30.8) 0.884(0.251-3.107)  0.847       
Office work/student 7(26.9) 0.904(0.259-3.271) 0.904 
House wife 7(26.9) 0.824(0.227-2.989) 0.824 
Others 4(11.515.4) I 
 
Previous TB  treatment        00 
Yes 5(19.2) 1.642(0.596-4.526) 0.337 
No 21(80.8) I  
HIV status                 
Reactive 3(11.5 ) 0.764(0.172-3.388) 0.723 
Non-reactive 5(17.2) I  
Diabetes mellitus                   
Yes 2(7.7) 1.70 (0.333-8.682) 0.521 
No 9(34.6) I  
Smoke cigarette   
 
Yes 2(7.7) 0.715(0.153-3.335) 0.669 
No 24(92.3) I  
Drink alcohol     
Yes 7(24.1) 0.699(0.279-1.754) 0.446 
No 19(75.9) I  
I-Reference category, COR- Crude Odds Ratio, CI-Confidence interval, N-Number, TB-Tuberculosis 
 
 










Isolation and detection of mycobacteria play an 
important role in the control and prevention of 
tuberculosis and tuberculosis like diseases (24). 
During the four month period of our study, a 
total of 275 presumptive pulmonary TB patients 
were enrolled, and 29(10.6%) of them were 
positive for Mycobacteria infection. Of these, 
the majority were MTBC 26(89.7%). 
M.peregrinum was the NTM species identified.  
A similar study on identification of 
mycobacteria in Nigeria reported that out of 270 
suspected pulmonary tuberculosis patients, 
26(9.5%) were infected with mycobacteria (25), 
which is comparable to our finding. However, 
higher isolation rates were reported from 
Tanzania, (32.5%) (26) and Ethiopia, (17.4%) 
(15).  
The overall magnitude of bacteriologically 
confirmed pulmonary tuberculosis in our study 
(9.5%) was lower than previous reports in 
Ethiopia (16.5%) (16), Tanzania (22.8%) (26) 
and Nigeria (28%) (27). However, our finding 
showed a higher burden than another study 
conducted in Nigeria (6.3%) (25). These may 
reflect the variations in the study population and 
laboratory method. Of the cultured confirmed 
TB, 32% (8/25) patients had normal chest x-ray 
results. This implies that the use of sputum 
culture in the diagnosis of active tuberculosis 
improves detection rates and ultimately leads to 
improved patient outcomes and reduced 
transmission of M. tuberculosis. 
Previous reports in Ethiopia from National 
Tuberculosis Reference Laboratory (6%) and 
Saint Peter Tuberculosis Specialized Hospital 
Laboratory (7%) indicated presence of NTM 
without confirmation and speciation (15,20). 
The present study unlike the former revealed 
higher percentage (10.3%) of confirmed 
nontuberculous mycobacteria. This finding is 
consistent with studies done in Iran (10.2%) (3) 
and Tanzania (9.7%) (26), but higher isolation 
rate was observed in USA (14%) (14) and 
Nigeria (15%) (27). This might be due to the 
variation in study population and laboratory 
method. 
The distribution of NTM species 
significantly varies across regions (10). Of the 3 
NTM isolated in this study, molecular technique 
showed that one NTM was typed as M. 
peregrinum. Studies carried out in some African 
countries identified M. peregrinum and other 
NTM species from sputum samples of 
presumptive pulmonary tuberculosis patients 
(28,29,8). Additionally, M. peregrinum 
implicated as a possible causative agent of 
pulmonary disease in human (30,31). However, 
the NTM isolates in this study were not 
evaluated by the diagnostic criteria for NTM 
disease published by the American Thoracic 
Society (ATS).  
In this study, a resistance proportion to at 
least one of the five anti-tuberculosis drug tested 
was 23.1% which is comparable to reports in 
Addis Ababa, Ethiopia (22.3%) (17) and Libya 
(24.1%) (32). However, higher resistance 
proportion was reported in other studies done in 
Ethiopia (27.4%) (18) and Kenya (30.1%) (33). 
This variation could be due to the fact that the 
latter two studies were conducted at referral sites 
for TB cases. A study done in East Gojam, 
Ethiopia, reported slightly lower level (20.23%) 
of drug resistance than our study (19). 
This study has some limitations. There was 
no follow-up of patients who were positive for 
nontuberculous mycobacteria even though 
reported to the concerned physician. The study 
was also limited to patients who were attended 
to in one hospital, but the information reported 
in this study could be a significant contribution 
to the existing knowledge on the burden of 
MTBC and nontuberculous mycobacteria. 
In conclusion, this study depicted that the 
majority of the isolated Mycobacteria from 
sputum samples of presumptive pulmonary 
tuberculosis patients were Mycobacterium 
tuberculosis complex (89.7%) and low extent of 
nontuberculous mycobacteria (10.3%). Of the 
isolated MTBC, 76.9% were susceptible to five 
anti-tuberculosis drugs. Therefore, further large 
scale study is needed to substantiate those results 
and to consider NTM as a differential diagnosis 
of pulmonary tuberculosis like disease.  
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